OMVOH Market Insights

Key Factors Driving OMVOH Market Growth

1. Expansion Into Crohn’s Disease Significantly Broadens Market Opportunity

OMVOH was initially approved by the FDA for moderately to severely active Ulcerative Colitis in October 2023 and received U.S. approval for Crohn’s disease in January 2025, substantially increasing its addressable patient population.

In the pivotal Phase III VIVID-1 Crohn’s disease study:

• 54.1% of patients achieved clinical remission at one year
• 48.4% achieved endoscopic response

These outcomes were superior to placebo and notable even among biologic-experienced patients.

2. Differentiated IL-23p19 Mechanism Supports Competitive Positioning

OMVOH selectively targets the IL-23p19 subunit, a validated inflammatory pathway in Inflammatory Bowel Disease. Lilly positions OMVOH as the first and only IL-23p19 antagonist with long-term efficacy data in both UC and CD.

The IL-23 class has become one of the fastest-growing segments in immunology due to strong efficacy and comparatively favorable safety profiles versus broader immunosuppressive agents. OMVOH competes against drugs such as Skyrizi and Stelara but differentiates itself through extensive histologic and bowel urgency outcome data.

3. Strong Long-Term Remission and Durability Data Increase Physician Confidence

Lilly continues to publish long-term extension data supporting durable efficacy:

• Over 90% of Crohn’s disease patients who achieved remission at Year 1 maintained remission through Year 2
• Nearly 90% sustained endoscopic response at two years

In ulcerative colitis, four-year extension data from the LUCENT program showed approximately 80% of responders maintained corticosteroid-free remission long term. Such durability is highly valuable in chronic IBD management and supports greater physician adoption.

4. Focus on Patient-Centric Outcomes Such as Bowel Urgency

OMVOH has shown clinically meaningful improvements in bowel urgency, one of the most disruptive symptoms for UC and CD patients. Lilly highlighted that OMVOH was the first pivotal Crohn’s disease trial to include bowel urgency outcomes in labeling discussions.

In the Phase 3b LUCENT-URGE study:

• Patients experienced a 55% reduction in daily bowel urgency episodes by Week 12. This patient-focused differentiation may help drive preference among gastroenterologists and patients. 

5. Rapid Global Regulatory and Reimbursement Expansion

Lilly is aggressively expanding OMVOH internationally. The drug has already secured approvals for UC in numerous global markets and is progressing through additional Crohn’s disease filings in Europe, Canada, Japan, and China.q

OMVOH Market Recent Breakthroughs and Developments

• In May 2026, New long-term data from Eli Lilly and Company show patients with moderately to severely active ulcerative colitis (UC) treated with Omvoh (mirikizumab-mrkz) achieved durable disease clearance through four years of continuous treatment. In the LUCENT-3 open-label extension study, 63.5% of Omvoh-treated patients who achieved disease clearance at one year sustained it at four years. These results will be presented at Digestive Disease Week® (DDW) and represent the first time an interleukin-23p19 (IL-23p19) inhibitor has demonstrated durable disease clearance through four years in people with UC. 

“OMVOH Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of OMVOH for approved indication like Crohn’s disease and Ulcerative colitis; as well as potential indication like Obesity in the 7MM. A detailed picture of OMVOH’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034.

It is provided in this report along with a detailed description of the OMVOH for approved and potential indications. The OMVOH market report provides insights about OMVOH’s sales forecast, mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. 

Further, it also consists of historical and current OMVOH performance, future market assessments inclusive of the OMVOH market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides an analysis of OMVOH sales forecasts, along with factors driving its market.

OMVOH Drug Summary

OMVOH is a humanized monoclonal antibody developed by Eli Lilly and Company for the treatment of moderately to severely active ulcerative colitis and Crohn’s disease in adults. The drug selectively targets the p19 subunit of interleukin-23 (IL-23), a key cytokine involved in chronic intestinal inflammation, thereby helping reduce inflammatory signaling and promote mucosal healing in patients with inflammatory bowel disease. OMVOH is administered initially through intravenous induction dosing followed by subcutaneous maintenance injections, offering a targeted biologic approach for long-term disease management. 

Clinical trials such as LUCENT and VIVID demonstrated significant rates of clinical remission, endoscopic improvement, and sustained response in patients with ulcerative colitis, including individuals previously exposed to biologic therapies. The therapy has been recognized for its durable efficacy and relatively favorable safety profile, with common adverse effects including upper respiratory tract infections, injection-site reactions, headache, arthralgia, and elevated liver enzymes, while monitoring for infections and hypersensitivity reactions is recommended during treatment.

The OMVOH market report provides OMVOH’s sales, growth barriers and drivers, post usage and approvals in multiple indications. 

Scope of the OMVOH Market Report

The OMVOH Market Report provides insights into:

• A comprehensive product overview including the OMVOH MOA, description, dosage and administration, research and development activities in approved indications like Crohn’s disease and Ulcerative colitis; as well as potential indications like Obesity.
• Elaborated details on OMVOH regulatory milestones and other development activities have been provided in the OMVOH market report.
• The report also highlights OMVOH‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The OMVOH market report also covers the patents information, generic entry and impact on cost cut.
• The OMVOH market report contains current and forecasted OMVOH sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The OMVOH market report also features the SWOT analysis with analyst views for OMVOH in approved and potential indications.

OMVOH Methodology

The OMVOH market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and OMVOH Sales Data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases. 

OMVOH Analytical Perspective by DelveInsight

• In-depth OMVOH Market Assessment

This OMVOH sales market forecast report provides a detailed market assessment of OMVOH for approved indications like Crohn’s disease and Ulcerative colitis; as well as potential indication like Obesity in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted OMVOH sales data uptil 2034.

• OMVOH Clinical Assessment

The OMVOH market report provides the clinical trials information of OMVOH for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

OMVOH Competitive Landscape

The OMVOH market report provides insights into competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

OMVOH Market Potential & Revenue Forecast

• Projected OMVOH Market Size and its key indications
• Estimated OMVOH sales potential (OMVOH peak sales forecasts)
• OMVOH Pricing strategies and reimbursement landscape

OMVOH Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• OMVOH Market positioning compared to existing treatments
• OMVOH Strengths & weaknesses relative to competitors

OMVOH Regulatory & Commercial Milestones

• OMVOH Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

OMVOH Clinical Differentiation

• OMVOH Efficacy & safety advantages over existing drugs
• OMVOH Unique selling points  

OMVOH Market Report Highlights

• In the coming years, the OMVOH market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the OMVOH market size.
• The OMVOH Companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence OMVOH’s dominance.
• Other emerging products for Crohn’s disease and Ulcerative colitis, as well as potential indication like obesity, are expected to give tough market competition to OMVOH and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones and developmental activities provides the current development scenario of OMVOH in approved and potential indications.
• Analyse OMVOH cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted OMVOH sales data until 2034 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of OMVOH in approved and potential indications.

Key Questions Answered in the OMVOH Market Report

• What is the class of therapy, route of administration and mechanism of action of OMVOH? How strong is OMVOH’s clinical and commercial performance?
• What is OMVOH’s clinical trial status in each individual indications such as Crohn’s disease and Ulcerative colitis, as well as potential indication like Obesity and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the OMVOH Manufacturers?
• What are the key designations that have been granted to OMVOH for approved and potential indications? How are they going to impact OMVOH’s penetration in various geographies?
• What is the current and forecasted OMVOH market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted OMVOH Sales in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan? 
• What are the other emerging products available and how are these giving competition to OMVOH for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is OMVOH? What is the duration of therapy and what are the geographical variations in cost per patient?

Stay updated with us for Recent Articles @ New DelveInsight Blogs